×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| VIMTA LABS LTD. | 993.13 | 188.94 | 975.64 | 4.21 | 3,650 | 60.0 |
| Orchid Pharma Limited | 1888.59 | 181.97 | 1729.29 | 3.59 | 3590 | 42.1 |
| GUFIC BIOSCIENCES LTD. | 2278.06 | 120.73 | 2269.11 | 1.2 | 3589 | 58.0 |
Vimta Labs Ltd., with Security Code 524394, is a leading player in the Healthcare Research- Analytics & Technology industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 80.8 | 82.2 | 72.3 | 80.1 | 78.3 | 80.2 | 83.1 | 88.5 | 94.4 | 97.6 |
| Expenses | 57.2 | 58.4 | 57.0 | 59.2 | 54.7 | 56.6 | 54.2 | 56.2 | 61.4 | 63.9 |
| Operating Profit | 23.6 | 23.8 | 15.3 | 20.9 | 23.6 | 23.6 | 28.9 | 32.3 | 33.1 | 33.7 |
| OPM % | 29.16% | 29% | 21.17% | 26.07% | 30.16% | 29.43% | 34.81% | 36.53% | 35.04% | 34.53% |
| Other Income | 0.7 | 0.6 | 2.0 | 0.9 | 0.5 | 0.7 | 0.7 | 1.2 | 1.6 | 1.7 |
| Interest | 0.2 | 0.4 | 0.6 | 0.5 | 0.5 | 0.5 | 0.4 | 0.6 | 0.4 | 0.3 |
| Depreciation | 8.0 | 8.5 | 8.9 | 8.6 | 8.0 | 8.1 | 8.2 | 9.7 | 9.2 | 9.9 |
| Profit before tax | 16.0 | 15.5 | 7.8 | 12.6 | 15.6 | 15.7 | 21.0 | 23.2 | 25.1 | 25.3 |
| Tax % | -23.3% | -25.2% | -24.5% | -24.9% | -24.1% | 25.7% | -22.1% | -26.7% | -26.8% | 25.2% |
| Net Profit | 12.3 | 11.6 | 5.9 | 9.5 | 11.8 | 11.6 | 14.6 | 21.0 | 18.3 | 18.9 |
| EPS in Rs | 2.73 | 2.58 | 1.32 | 2.1 | 2.63 | 2.59 | 3.23 | 4.67 | 0 | 4.21 |
| Metrics | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79.9 | 77.4 | 81.8 | 83.5 | 73.4 | 81.7 | 79.7 | 81.8 | 84.7 | 89.9 |
| Expenses | 54.5 | 55.9 | 57.6 | 58.8 | 57.5 | 59.8 | 55.3 | 57.2 | 54.8 | 56.8 |
| Operating Profit | 25.4 | 21.5 | 24.2 | 24.7 | 15.9 | 21.8 | 24.4 | 24.5 | 29.9 | 33.1 |
| OPM % | 31.77% | 27.73% | 29.55% | 29.53% | 21.64% | 26.74% | 30.64% | 29.99% | 35.28% | 36.79% |
| Other Income | 0.8 | 1.1 | 0.7 | 0.6 | 2.0 | 0.9 | 0.5 | 0.7 | 0.7 | 1.2 |
| Interest | 0.8 | 0.7 | 0.2 | 0.4 | 0.6 | 0.5 | 0.5 | 0.5 | 0.4 | 0.6 |
| Depreciation | 7.6 | 7.8 | 8.0 | 8.5 | 8.9 | 8.7 | 8.1 | 8.2 | 8.3 | 9.8 |
| Profit before tax | 17.8 | 14.1 | 16.6 | 16.3 | 8.4 | 13.5 | 16.3 | 16.5 | 21.9 | 23.9 |
| Tax % | -25.6% | -27.3% | -23.4% | -25.2% | -24.6% | -25% | 24.2% | -25.7% | -22.3% | 26.8% |
| Net Profit | 13.2 | 10.2 | 12.7 | 12.2 | 6.3 | 10.1 | 12.4 | 12.3 | 15.2 | 21.5 |
| EPS in Rs | 2.92 | 2.25 | 2.82 | 2.7 | 1.42 | 2.25 | 2.75 | 2.73 | 3.38 | 4.78 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 58% |
| 3 Years: | 17% |
| TTM: | 66% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 71% |
| 3 Years: | 43% |
| 1 Year: | 99% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 15% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 24% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 71% |
| 3 Years: | 43% |
| 1 Year: | 99% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|